MACROGENICS INC
Antibody-based cancer therapeutics using novel antibody engineering platforms
New patent ·
- Sector
- Biotech
- Headquarters
- Rockville, MD
- Latest Form D
- $12M, Jan 2011
- Total capital
- $12M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $12M
- 1 Form D · last Jan 2011
- 189 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 16
- 24 pending · first 2023
- Rank in peer group#21 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$12M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#21 · top 1%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Arnold OronskyDirectorNamed in SEC Form D filings
- Ed HurwitzDirectorNamed in SEC Form D filings
- James KarrelsExecutive OfficerNamed in SEC Form D filings
- Ken GalbraithDirectorNamed in SEC Form D filings
- Michael SteinmetzDirectorNamed in SEC Form D filings
- Paulo CostaDirectorNamed in SEC Form D filings
Show all 8 people
- Paul SekhriDirectorNamed in SEC Form D filings
- Scott KoenigExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 16 granted of 40- New patentCovalent Diabodies and Uses ThereofUSPTOUS 12,760,106
- PendingCompound Targeting IL-23A And Tnf-alpha And Uses ThereofUSPTOApplication 19547752
- PendingANTI-PD-1 Antibodies And Uses ThereofUSPTOApplication 19340473
Show all 40 patent records
- Covalent Diabodies and Uses ThereofOct 13, 2026 · US 12,760,106Granted
- Compound Targeting IL-23A And Tnf-alpha And Uses ThereofAug 27, 2026 · Application 19547752Pending
- ANTI-PD-1 Antibodies And Uses ThereofJul 16, 2026 · Application 19340473Pending
- PD-1-BINDING Molecules And Methods Of Use ThereofMay 14, 2026 · Application 19445391Pending
- LAG-3-Binding Molecules and Methods of Use ThereofApr 14, 2026 · US 12,600,779Granted
- PD-1-BINDING Molecules And Methods Of Use ThereofJan 27, 2026 · US 12,534,531Granted
- Pharmaceutical Compositions Of A PD-1 Antibody And Use Of The SameNov 13, 2025 · Application 19275898Pending
- ANTI-PD-1 Antibodies And Uses ThereofOct 21, 2025 · US 12,448,448Granted
- Bi-specific Monovalent Diabodies That Are Capable Of Binding CD19 And CD3, And Uses ThereofOct 9, 2025 · Application 19242270Pending
- CD137 Binding Molecules And Uses ThereofOct 7, 2025 · US 12,435,155Granted
- Covalently Bonded Diabodies Having Immunoreactivity With PD-1 And LAG-3, And Methods Of Use ThereofOct 2, 2025 · Application 19239433Pending
- Pharmaceutical Compositions Of A PD-1 Antibody And Use Of The SameJul 22, 2025 · US 12,364,756Granted
- Methods For The Use Of A B7-H3 Antibody-drug Conjugate In Combination With A PD-1 X CTLA-4 Bispecific MoleculeMay 1, 2025 · Application 18836888Pending
- CD3-Binding Molecules Capable of Binding to Human and Non-Human CD3Apr 17, 2025 · Application 18746758Pending
- ADAM9-Binding Molecules, and Methods of Use ThereofApr 10, 2025 · Application 18915947Pending
- Antibodies Reactive with B7-H3, Immunologically Active Fragments Thereof and Uses ThereofDec 12, 2024 · Application 18794328Pending
- Pharmaceutical Compositions Of A B7-H3 Antibody And Use Of The SameOct 10, 2024 · Application 18577945Pending
- CD3-Binding Molecules Capable of Binding to Human and Non-Human CD3Jul 30, 2024 · US 12,049,501Granted
- Bispecific Binding Molecules That Are Capable Of Binding CD137 And Tumor Antigens, And Uses ThereofJul 11, 2024 · Application 18442857Pending
- HER2/neu-Specific Antibodies and Methods of Using SameJul 2, 2024 · US 12,024,569Granted
- MULTl-CHAIN POLYPEPTIDE-CONTAINING TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENSJun 6, 2024 · Application 18484921Pending
- Methods For Increasing Efficacy Of Immunoconjugates Targeting ADAM9 For The Treatment Of CancerMay 23, 2024 · Application 18280896Pending
- Tri-specific Binding Molecules That Specifically Bind To Multiple Cancer AntigensApr 11, 2024 · Application 18320599Pending
- Bispecific Binding Molecules That Are Capable Of Binding CD137 And Tumor Antigens, And Uses ThereofMar 26, 2024 · US 11,942,149Granted
- Methods Of Using Bispecific Molecules Having Immunoreactivity With PD-1 And CTLA-4Mar 14, 2024 · Application 18499658Pending
- Variant CD3-Binding Domains and Their Use in Combination Therapies for the Treatment of DiseaseFeb 8, 2024 · Application 18321354Pending
- Compound Targeting IL-23A And B-cell Activating Factor (baff) And Uses ThereofJan 30, 2024 · US 11,884,744Granted
- METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS ALTERED AFFINITIES FOR FcyRActivating and FcyRInhibitingJan 18, 2024 · Application 18462672Pending
- LAG-3-Binding Molecules and Methods of Use ThereofJan 2, 2024 · US 11,858,991Granted
- Bi-Specific Monovalent Diabodies That are Capable of Binding CD19 and CD3, and Uses ThereofDec 14, 2023 · Application 18186353Pending
- Methods Of Using Bispecific Molecules Having Immunoreactivity With PD-1 And CTLA-4Dec 12, 2023 · US 11,840,571Granted
- Covalent Diabodies and Uses ThereofNov 30, 2023 · Application 18164952Pending
- Compound Targeting IL-23A And Tnf-alpha And Uses ThereofNov 30, 2023 · Application 18178783Pending
- Multi-chain Polypeptide-containing Tri-specific Binding MoleculesNov 21, 2023 · US 11,820,818Granted
- Bispecific CD16-Binding Molecules and Their Use in the Treatment of DiseaseOct 24, 2023 · US 11,795,226Granted
- Methods for the Treatment of Disease Using Immunoglobulins Having Fc Regions with Altered Affinities for FcgammaRactivating and FcgammaRinhibitingOct 17, 2023 · US 11,787,871Granted
- Methods For The Use Of A PD-1 X CTLA-4 Bispecific MoleculeOct 5, 2023 · Application 18006294Pending
- B7-H3 Directed Antibody Drug ConjugatesAug 31, 2023 · Application 18151146Pending
- Methods For The Use Of A B7-H3 Antibody-drug Conjugate Alone Or In CombinationJul 20, 2023 · Application 17998455Pending
- Tri-specific Binding Molecules That Specifically Bind To Multiple Cancer AntigensJul 11, 2023 · US 11,697,684Granted
Related companies, and why
- nferenceSimilar federal contract value in Biotech · null in contracts
- HDL THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- Encellin, Inc.Similar federal contract value in Biotech · null in contracts
- Akebia Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Silo Pharma, Inc.Similar federal contract value in Biotech · null in contracts
- FENNEC PHARMACEUTICALS INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .